These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24094935)

  • 1. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.
    Ciolino JB; Stefanescu CF; Ross AE; Salvador-Culla B; Cortez P; Ford EM; Wymbs KA; Sprague SL; Mascoop DR; Rudina SS; Trauger SA; Cade F; Kohane DS
    Biomaterials; 2014 Jan; 35(1):432-9. PubMed ID: 24094935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma.
    Xu J; Ge Y; Bu R; Zhang A; Feng S; Wang J; Gou J; Yin T; He H; Zhang Y; Tang X
    J Control Release; 2019 Jul; 305():18-28. PubMed ID: 31103677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment.
    Cheng YH; Tsai TH; Jhan YY; Chiu AW; Tsai KL; Chien CS; Chiou SH; Liu CJ
    Carbohydr Polym; 2016 Jun; 144():390-9. PubMed ID: 27083831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma.
    Dang H; Dong C; Zhang L
    Pharm Dev Technol; 2022 Feb; 27(2):127-133. PubMed ID: 34704874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
    Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
    PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma.
    Taniguchi EV; Kalout P; Pasquale LR; Kohane DS; Ciolino JB
    Ther Deliv; 2014 Oct; 5(10):1077-83. PubMed ID: 25418267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma.
    Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5629-37. PubMed ID: 23868986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and performance of latanoprost-loaded hydrogels as a lacrimal suppository for the treatment of glaucoma.
    Xiao S; Ma A; Ma Y; Bai H; Zhang B; Li J; Zhou H
    J Biomater Appl; 2023 Apr; 37(9):1529-1541. PubMed ID: 36693765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
    Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
    J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery.
    Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO
    J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma.
    Kjellgren D; Douglas G; Mikelberg FS; Drance SM; Alm A
    Acta Ophthalmol Scand; 1995 Jun; 73(3):233-6. PubMed ID: 7493234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latanoprost for uncontrolled glaucoma in a compassionate case protocol.
    Patelska B; Greenfield DS; Liebmann JM; Wand M; Kushnick H; Ritch R
    Am J Ophthalmol; 1997 Sep; 124(3):279-86. PubMed ID: 9439353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.